Trial Profile
A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms ALPHA-MM
- 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database,
- 24 Apr 2012 Company (Novartis Pharmaceuticals Corporation) added as trial sponsor as reported by ClinicalTrials.gov.
- 16 Mar 2010 Planned end date (1 May 2008) added as reported by ClinicalTrials.gov.